LIVE PROGRESSION FREE

In 2 different trials, patients lived progression free longer when treated with sarclisa plus other therapies.

Trial 1: At a median follow-up of 44 months, patients lived progression free for a median of 41.7 months with SARCLISA + Kyprolis (carfilzomib) and dexamethasone (Kd) vs 20.8 months with Kd alone. At the time of this analysis, 56% (101 of 179 patients) lived progression free with SARCLISA + Kd vs 45% (55 of 123 patients) treated with Kd alone. In an earlier analysis, at a median follow-up of 20.7 months, 74% (133 of 179 patients) lived progression free with SARCLISA + Kd vs 59% (73 of 123 patients) treated with Kd alone.

Trial 2: At a median follow-up of 11.6 months, patients lived progression free for a median of 11.53 months with SARCLISA + Pomalyst® (pomalidomide) and dexamethasone (Pd) vs 6.47 months with Pd alone. At the time of this analysis, 53% (81 of 154 patients) lived progression free with SARCLISA + Pd vs 42% (64 of 153 patients) treated with Pd alone.

A median is the middle number in a group of numbers ordered from smallest to largest.